Silver crumb is a common chronic inflammatory skin disease, and Sakuchio is a widely used biological agent that works by inhibiting white cellulin – 17A. However, the use of Sukuchio monotherapy by some patients may be ineffective. When Sakuchio has failed, other biological agents need to be carefully selected.
Consideration of white cellulose – 12/23 inhibitors
– Ussnu resistance: it regulates the immune system and inhibits inflammation by blocking the p40 units common to white cell media 12 and white cellulin 23; For some patients who use the Sakuchiyo to fight effectively, usnu resistance may be an effective alternative. It is given in a relatively convenient manner and is usually maintained at a certain time interval after the initial dose. For example, some persons with moderate-heavy scavenging silver crumbs are still active in the aftermath of the Sukucyo monotherapy, which has been converted into usnu monotherapy, and have gradually improved the symptoms of red spots and crumbs in their skin. Also, their long-term safety data are significant, and the adverse effects are mostly light and reversible, such as in the injection sector.
– Guisechio is one-sided: it is mainly a p19 unit of white cellulin – 23, which precisely inhibits access to specific inflammations. For those who are poorly responding to the Sakuchio monotherapy, especially for those types of silver crumbs driven mainly by white cellulin-23, the Guisechio monotherapy may be more effective. Clinical studies have shown that, among some of the hard-to-do patients with silver crumbs, Guisecchio alone can effectively reduce the area and severity of silver crumbs (PASI) and improve the quality of life of patients.
II. Cause of death – Alpha (TNF – alpha) inhibitor
– Adamu is a monoclonic antibodies that combines TNF-α and disrupts its biological activity. In the treatment of silver crumbs, when Sakuchiyo is less effective, Adamu alone can play an inflammatory role. It has been applied in clinical practice for many years, with a wealth of clinical experience and research data to support its effectiveness. For people with arthropod-like silver crumbs, the Adam single resistance not only improves skin disease but also mitigates joint symptoms. However, the use of the Adawood monologue also requires attention to its possible adverse effects, such as increased risk of infection, including tuberculosis, so that relevant screening is required prior to use.
– Inflisi Monologue: is a human rat-embedded monoclon antibodies that inhibit interaction with receptors by combining with TNF-α. In a number of cases of silver crumbs against Sakuchio alone, Inflisi alone can induce a reduction. It usually uses intravenous infusion, which works relatively quickly. However, because of its structure, which contains rat-source components, there may be some immunogenic reactions, such as the infusion response, requiring close observation of the patient during the infusion.
Exploration of new biological agents
– Dual-specific antibodies: These can be targeted at two different target points at the same time, for example, for white cellulin at the same time – 17 and another inflammation-related molecule. They provide new treatment thinking for those who have failed to treat single target biological agents (e.g., Sakuchio). Although applications in the field of silver crumb treatment are still at the research stage, preliminary studies have shown their potential effectiveness and good tolerance.
– Small Molecular Biological Agents: Small Molecular Biological Agents have advantages such as oral delivery, compared to traditional Large Molecular Biological Agents. They play an anti-inflammatory role by inhibiting the transmission of signals within cells. The successful development and application of small molecular biological agents will provide easier treatment options for patients who have failed in the Sakuchio monotherapy.
When the single treatment of silver crumbs failed, doctors needed to take into account the specific conditions of the patient, his or her treatment response, his or her complications and financial factors, and to select the biological agents most suitable for the patient in order to achieve the best treatment. At the same time, patients need to follow closely the changes in their symptoms and possible adverse reactions in the use of new biological agents and to communicate with doctors in a timely manner.
